Screening for diabetic retinopathy can help to prevent this complication, but evidence regarding frequency of screening is uncertain. This paper systematically reviews the published literature on the relationship between screening intervals for diabetic retinopathy and the incidence of visual loss. The PubMed and EMBASE databases were searched until December 2012. Twenty five studies fulfilled the inclusion criteria, as these assessed the incidence/prevalence of sight-threatening diabetic retinopathy in relation to screening frequency. The included studies comprised 15 evaluations of real-world screening programmes, three studies modelling the natural history of diabetic retinopathy and seven cost-effectiveness studies. In evaluations of diabetic retinopathy screening programmes, the appropriate screening interval ranged from one to four years, in people with no retinopathy at baseline. Despite study heterogeneity, the overall tendency observed in these programmes was that 2-year screening intervals among people with no diabetic retinopathy at diagnosis were not associated with high incidence of sight-threatening diabetic retinopathy. The modelling studies (non-economic and economic) assessed a range of screening intervals (1-5 years). The aggregated evidence from both the natural history and cost-effectiveness models favors a screening interval >1 year, but ≤2 years. Such an interval would be appropriate, safe and cost-effective for people with no diabetic retinopathy at diagnosis, while screening intervals ≤1 year would be preferable for people with pre-existing diabetic retinopathy. A 2-year screening interval for people with no sight threatening diabetic retinopathy at diagnosis may be safely adopted. For patients with pre-existing diabetic retinopathy, a shorter interval ≤1 year is warranted.
Introduction
Diabetic retinopathy commonly complicates diabetes mellitus [1] and meets the World Health Organization (WHO) criteria of suitability for screening [2] . It is a major cause of vision loss worldwide. Approximately one third of people with diabetes have diabetic retinopathy, and a third of those with diabetic retinopathy may have sight-threatening diabetic retinopathy, defined as clinically significant proliferative retinopathy or macula oedema [1] . The prevalence of diabetic retinopathy is projected to increase in the coming decades. The number of Americans aged 40 years or older, for example, with diabetic retinopathy and sight-threatening diabetic retinopathy is predicted to triple by 2050 [3] . In China, the prevalence of diabetic retinopathy among people with diabetes reaches 43% [1] , with up to 9.2 million people in rural areas having diabetic retinopathy, including 1.3 million with sight-threatening diabetic retinopathy [1] .
The natural history of diabetic retinopathy is relatively well understood, with recognizable stages. Major risk factors for developing diabetic retinopathy include duration of diabetes [4, 5] , severity of hyperglycaemia [6] [7] [8] , hypertension [9] and dyslipidaemia [10] . Once sight-threatening diabetic retinopathy is present, the progression is rapid and complications are unpredictable. Twenty years after diagnosis, almost all people with Type 1 diabetes mellitus and 60% of people with Type 2 diabetes mellitus will have some degree of diabetic retinopathy [4, 5] .
There are precise, safe and accepted screening tests (ophthalmoscopy and fundus photography) for diabetic retinopathy [11] . Glycaemic and blood pressure control may prevent the progression of diabetic retinopathy [7, 9] . Appropriately timed laser photocoagulation therapy and, to a certain extent, Correspondence to: Justin B. Echouffo-Tcheugui. E-mail: jechouf@emory.edu anti-vascular endothelial growth factor (VEGF), can dramatically reduce progression of sight-threatening diabetic retinopathy to vision loss [12] . However, large numbers of eligible patients requiring these preventive therapies may not actually be receiving them. In the USA, up to 60% of patients requiring vision-preserving laser surgery may not be receiving optimally timed retinal photocoagulation [13] .
Several national agencies recommend annual screening and early treatment for sight-threatening diabetic retinopathy lesions [14] [15] [16] . However, given the increasing demand for ophthalmology services and costs associated with ophthalmic care, an optimal screening interval has been debated, with some suggesting the adoption of longer intervals for patients with no background retinopathy, with more frequent surveillance examinations for those at high risk [17] [18] [19] . Indeed, there is accumulating evidence that the natural history of diabetic retinopathy is sufficiently slow that 2-yearly retinal screening, or even longer, may be safe for some patients with diabetes [20] , especially as information technology underpinning call-recall systems within screening programmes is such that a more effective approach to organizing retinal screening could allow moving towards a biennial retinal screening programme. Consequently, screening low-risk individuals too frequently implies an inefficient use of limited healthcare resources.
Here, we systematically review the evidence regarding the effect of screening intervals for diabetic retinopathy on the incidence of sight-threatening diabetic retinopathy/visual loss, and attempt to synthesize the available data in order to guide the design of appropriate policy recommendations.
Methods

Data sources
We searched the PubMed and EMBASE electronic databases for articles published until December 2012. We used a combination of terms related to screening for diabetic retinopathy (see also Supporting Information, Appendix S1). Titles, abstracts and/or full texts of articles identified through these searches were sequentially screened for inclusion ( Fig. 1 ) and electronic searches were supplemented by scanning the references lists of relevant publications. When published data were unclear, we contacted authors for further information.
Inclusion and exclusion criteria
Studies were included if they: 1. assessed a real-world diabetic retinopathy screening programme and reported the incidence of sight threatening retinopathy or blindness in relation to the screening interval; 2. modelled the effect of varying screening interval for diabetic retinopathy on the costs and/or cost-effectiveness of diabetic retinopathy screening; or 3. modelled the effect of varying screening interval for diabetic retinopathy on the incidence of sight-threatening diabetic retinopathy or blindness.
Data extraction and quality assessment
Two reviewers (JBE-T and MKA) extracted relevant data, including characteristics of the study population, study setting, screening modalities, screening frequency, incidence of sight-threatening diabetic retinopathy or blindness, and measures of efficiency of the screening interval. Disagreements were resolved by a third reviewer (KMN). To our knowledge, there is no commonly agreed-upon unifying framework to evaluate screening programmes and/or studies of the natural history of diabetic retinopathy; we therefore focus on the individual characteristics of each study, giving more credit to well-designed, large, prospective studies with appropriate measures of outcomes. Although not originally designed for use in review articles, the Drummond and Jefferson evaluation scheme [21] for evaluating the quality of economic studies appeared to be a consensual tool that has been previously used [22] ; we therefore used it for economic studies (see also Supporting Information, Appendix S2).
Results
Of the 25 studies included in this review ( Fig. 1 ), 15 could be characterized as evaluations of actual screening programmes [17, 19, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , three as studies modelling the natural history of the disease [35] [36] [37] , seven were economic modelling studies that explored screening interval (five cost-effectiveness studies [38] [39] [40] [41] [42] , one a cost-utility study [18] and one combined cost-effectiveness and cost-utility analyses [43] ).
Screening studies
Screening programme evaluations examined the relationship between sight-threatening diabetic retinopathy occurrence and the frequency of screening (Table 1) , either as a primary [17, [27] [28] [29] [30] 32] or a secondary objective [19, [23] [24] [25] [26] 31, 33, 34, 44] . None of these studies were conducted in regions other than the USA, Europe and Australia. Four studies were hospital-based [23, 24, 28, 30] and the remainder were population-based. Their sample size varied from 185 to 57 199. Six of these studies exclusively recruited Caucasians [19, [23] [24] [25] [26] 32] and seven included non-white participants [17, 27, 29, 31, 33, 34, 44] , but had a majority of Caucasians. In two studies, the ethnicity of participants was not clearly reported, but given the setting of these studies it was logical to infer that the vast majority of their participants were Caucasians [28, 30] . When clearly reported, the age of participants ranged from 15 to 99 years. One study focused on children and adolescents exclusively [28] . The average duration of ª 2013 The Authors. Diabetic Medicine ª 2013 Diabetes UK diabetes at first screening varied between 0 and 15 years. Thirteen of the 15 studies were retrospective cohorts and two were prospective cohorts. One study reported using ophthalmoscopy alone to ascertain diabetic retinopathy [23] , fundal photography alone was used in nine studies [25, [27] [28] [29] [30] [32] [33] [34] 44] , and a combination of ophthalmoscopy and fundal photography was used in four studies [19, 24, 26, 31] . The vast majority of the 15 screening studies addressed screening for diabetic retinopathy in Type 1 and Type 2 diabetes together [19, [23] [24] [25] [26] [29] [30] [31] 44] . The screening studies provide unique information based on actual risk among screened individuals, the majority of whom were not receiving ophthalmic care. The appropriate screening interval was variable, ranging from 1 year [44] to 4 years [30] in people with no diabetic retinopathy at baseline. Despite the between-studies variation, the overall tendency observed was that a screening interval > 1 year would be appropriate and safe in people with no diabetic retinopathy at diagnosis, based on the extremely low rate of patients advancing from no diabetic retinopathy to sight-threatening diabetic retinopathy in less than 2-3 years. Twelve of the 15 studies supported a diabetic retinopathy screening interval > 1 year [17, 19, 24, [26] [27] [28] [29] [31] [32] [33] [34] 44] . The reported screening compliance rate varied from 21% [27] to 28% [26] .
A single study assessed the appropriate surveillance intervals for those with diabetic retinopathy at diagnosis, showing that a 1-year screening interval in the case of background retinopathy and 0.3 of a year for mild proliferative diabetic retinopathy, respectively, would be associated with a 95% probability of remaining free of sight-threatening diabetic retinopathy for patients with Type 2 diabetes [17] . Corresponding figures for Type 1 diabetes were 1.3 of a year for background and 0.4 of a year for pre-proliferative diabetic retinopathy [27] . These were the only studies that assessed the appropriate surveillance intervals for those with diabetic retinopathy at diagnosis [17, 27] . Their findings are consistent with current consensus in the medical community that yearly or more frequent screening for people with any sign of diabetic retinopathy should be the norm [12] .
Some of the screening studies supporting an interval > 1 year (e.g. a 2-year interval) included large-sample-size, population-based cohorts with extended follow-up and/or were specifically designed to assess the relationship between screening interval and incidence of sight-threatening diabetic retinopathy or blindness [17, 27, 29, 33, 34] , thus offering more robust evidence on the frequency of screening for diabetic retinopathy. However, other studies putting forward similar recommendations were relatively small in size, [19, 23, 24, 26, 28, 30, 31] or were hospital based [28, 30] . Studies supporting annual screening were not always specifically designed to examine the relationship between less frequent screening intervals and incidence of sightthreatening diabetic retinopathy or blindness [25, 44] . Furthermore, the largest of these studies used the proportion of blindness attributable to diabetic retinopathy as the main outcome and information about blindness was obtained from a registry [44] . In brief, the vast majority of evaluations of real-world diabetic retinopathy screening programmes supported a screening interval > 1 year.
Modelling studies
Natural history models
Modelling studies of the natural history are shown in Table 2 . A brief summary of the key specificities of each of these studies are presented below.
Using a hypothetical population and a range of sensitivities and specificities, to compare annual or biennial screening until background diabetic retinopathy develops and then examination 6 monthly or more frequently, Davies et al. found that biennial screening is a safe and efficient strategy, provided that patients' compliance and screening sensitivities are both high [35] . The net benefit of reducing the screening interval for those with no diabetic retinopathy from 2 years to 1 year would range from 0.25-0.42 years of sight saved per person, depending on screening methods used or the screener (ophthalmologist, general practitioner or optometrist).
Two Taiwan-based studies used data from real-world screening programmes to derive the appropriate screening interval for diabetic retinopathy [36, 37] . None of these models included the pathway to blindness through maculopathy.
Tung et al. advocated annual screening on the basis of the incidence of blindness reduction for various screening regimens: annual 94.4%; biennial 83.9%; 3-year 70.2%; 4-year 57.2%; 5-year 45.6% [36] . The best level of retinopathy in each of the two eyes was used for patients with asymmetric levels of severity; a sensitivity analysis choosing the worst eye was conducted and found that estimates of the efficacy for annual screening, biennial screening and 4-yearly screening regimes were reduced to 40, 37 and 34%, respectively. Although the absolute benefit diminished, the differences in benefits with annual screening and biennial screening against 4-yearly screening were not substantial. The study of Tung et al. [36] did not comprehensively describe the screening intervals/strategies and made no clear distinction between screening and surveillance once diabetic retinopathy is detected. Thus, the length of the surveillance once diabetic retinopathy is diagnosed was unclear. Screening was started 6 years after the diagnosis of diabetes; this delay may have led to a higher number of people with advanced stages of retinopathy when first seen. In addition, the average transition time from the mildest form of diabetic retinopathy to proliferative retinopathy in Tung et al.'s study was 10.8 years [36] . Thus, a 2-year screening interval in people with no diabetic retinopathy would still be less than one fifth of this interval.
Liu et al. advocated biennial screening after finding that annual screening, biennial screening and a 4-yearly screening regime can lead to 54, 51 and 46% reductions in blindness, respectively [37] . They used data from an ophthalmic care centre where patients may have had better care and potentially a lower rate of diabetic retinopathy progression. However, they accounted for the levels of compliance and metabolic control, making their model more close to reality. They chose the best level of retinopathy in each of the two eyes from all patients with asymmetric levels of severity; this may raise concern as to whether this can affect the optimal interval for screening patients with non-proliferative diabetic retinopathy. Nonetheless, a sensitivity analysis choosing the worst eye found that differences in benefits with annual screening and biennial screening against 4-yearly screening were not substantial.
Economic studies
Economic modelling studies evaluated the cost-effectiveness or cost-utility of various screening intervals (Table 3) . Two studies addressed screening for diabetic retinopathy in Type 1 and Type 2 diabetes [39, 41] and five addressed screening for Type 2 diabetes only [18, 38, 40, 42, 43] . As indicated in Table 3 and in the Supporting Information (Appendix S2), economic studies generally followed the key steps of economic modeling, with a good description of the model or simulation, along with source of data, costs and outcome measures. The vast majority of these studies favoured a screening interval > 1 year for people without diabetic retinopathy at baseline. Given the heterogeneity of assumptions used to conduct these studies, we summarize the key aspects of individual studies below.
Dasbach et al. [41] examined three cohorts of incident cases of diabetes, using two time horizons (10 and 60 years), and concluded that annual screening would be better than biennial screening. The 60-year net benefit conferred by an annual compared with a biennial programme would be 28-36 years of sight saved for 1000 younger-onset patients, 7-9 years for 1000 older insulin-using patients and 3-4 years for 1000 older patients not using insulin. Over a 10-year time horizon, for the young patient cohort taking insulin, the incremental cost-effectiveness ratio was £2351.38-2554.55 ($3553-3860) per sight year saved for 1-year screening and £2522.78-2624.7 ($3812-3966) for 2-year screening. However, outcomes did not include macular oedema or values for non-discounted sight years, and were unclear as to whether the rates of disease progression and death were derived from the study cohort or not. The major inputs of disease progression and mortality were not varied, which is potentially inadequate.
Javitt et al. [38] found that changing screening frequency from 1 year to 2 years would have no detrimental effects on years of sight saved, while demonstrating positive effects of reducing the costs for patients with no or mild retinopathy. Screening and treatment for diabetic retinopathy saved £164.13 ($248) annually and 53 986 person-years of sight in total. Nevertheless, for those with moderate non-proliferative or more advanced retinopathy, 8960 extra years of sight would be saved by a 1-year programme over the lifetime of the cohort ucode>-equating to 15.6 years per 1000 patients This model did not provide clear information on the exact figures for sight saved by different screening intervals for those with no baseline retinopathy, or include sensitivity analysis for different intervals. Their methods for determining annual and cohort cost and sight savings are not clearly stated and benefits are from treatments for all types of diabetic retinopathy.
Vijan et al. [18] showed that annual screening is more effective; however, for most patients, the costs of annual screening are considerable, with little marginal benefit when compared with screening every other or every third year. The marginal cost-effectiveness ratio of 1-year screening vs. 2-year screening was £71150.12 ($107 510/)quality-adjusted life year gained, 2-year screening vs. 3-year was £32931.17 ($49 760/) quality-adjusted life year gained; 3-year screening vs. 5-year screening was £19959.89 ($30 160/) quality-adjusted life year gained. The cost-effectiveness ratio was highest for patients whose onset of Type 2 diabetes occurred at a younger age and whose glycaemic control is poor. Vijan et al. addressed the limitations of a single perspective, through an examination of the government or society perspectives in a sensitivity analysis, and recommended a 2-year screening interval, with the option of tailoring the screening approach to the individual, so that those with the poorest glycaemic control would be screened more often. An alternate and safer option would be annual screening for all patients, but offering 2-or 3-year screening to those with good glycaemic control and with no retinopathy at baseline was considered appropriate. Vijan et al. [18] did not provide a basis for their choice of utility value (0.69) for blindness and lesser levels of visual impairment. The utility value for blindness had the biggest impact on cost-effectiveness in the sensitivity analysis, with annual screening appearing to be cost-effective at 0.48. Other studies defined utility values ranging from 0.60 to 0.86 (depending on severity of vision loss) [22] . Also, the assumed compliance rate in the model was 100%, which is unrealistic. The model overlooked potential variations in retinopathy risk in minority populations in the USA as these groups were not represented in UK Prospective Diabetes Study (UKPDS) (from which the input estimates were derived) [7] . Furthermore, the real-world accuracy for detection is probably lower than that modelled, and the prevalence of diabetic retinopathy was derived from a national US survey that included only a single photograph of each eye (sensitivity for retinopathy, 60%), rather than the criterion standard 7-field photography. Similarly, progression of disease was inferred from clinical trials in which participants are not representative of the overall population [45, 46] . Davies et al. [39] showed that screening less than once a year would not be cost-effective. The best cost-effectiveness ratio was for annual screening and 6-month follow-up after the detection of background diabetic retinopathy, at a cost of £449 200 per year with £2842 per sight year saved. Screening intervals were found to be a key area of uncertainty, with a trade-off between the intervals, screening sensitivity and compliance. However, they found that increasing surveillance intervals to annual intervals once non-proliferative diabetic retinopathy was detected rendered results on biennial screening (those with no diabetic retinopathy on previous examinations) robust to such real-world fluctuations. A 2-year screening frequency, before the detection of any retinopathy, was associated with a 10% reduction in sight years saved, and an 8% reduction in the cost per sight year saved. Davies et al. [39] did not discount for costs and benefits and the non-assessment of patient costs or cost benefits of preventing blindness. They explored the benefits of dividing patients into groups, based on HbA 1c , and recalling them at different intervals, but such an approach may not be practical in an actual screening programme. They also combined screening and surveillance intervals, but sensitivity analysis found that biennial screening was cost-effective if surveillance increased to at least annual once any form of diabetic retinopathy was detected on screening.
Using an ethnically mixed population (adjusting for the higher prevalence of diabetes in ethnic minorities), and various sensitivities and specificities of several screening methods conducted by different types of health personnel, Brailsford et al. compared the minimum and maximum cost for years of sight saved of various screening policies [47] . They indicated that, without financial constraints on a healthcare system, screening using a gold standard technology in a hospital setting every 6 months (maximum cost-effectiveness ratio: £5000/year of sight saved) can be delivered. In contrast, if saving the maximum number of sight years per pound spent is the objective, screening people aged 30-60 years every 30 months with a mobile camera would be appropriate (minimum cost-effectiveness ratio: £1259/year of sight saved). This suggests that a 30-month screening interval for diabetic retinopathy can be adopted; however, healthcare systems that can afford to pay more to prevent more cases of blindness may well choose not to adopt the described minimum cost-effectiveness scenario. Brailsford et al.
[47] did not consider compliance, an important variable in relation to screening intervals.
In a Taiwan-based model, using information on disease characteristics and costs data from a real-life community-based screening programme, Tung et al. [43] found that efficacy and utility decreased, while cost increased with the length of the screening/surveillance interval. For example, the costs per sight year saved were (in New Taiwan dollars) £1871.17($NT84 311) for no screening, £465.36 ($NT20 962) for 16 annual screening, £554.78 ($NT24 990) for biennial screening, £684.8 ($NT30 847) for 3-year screening, £831.06 ($NT37 435) for 4-year screening and £98.77 ($NT4449) for 5-year screening. The authors concluded that the ideal screening frequency should be annual. By using data from a real-life programme data, Tung et al. [43] probably estimated the true benefit of diabetic retinopathy screening more closely than in other modelling studies. However, the programme was relatively small (n = 725 patients), thus possibly not representative of patients with Type 2 diabetes. Moreover, the analysis did not consider the sensitivity and specificity of various diabetic retinopathy screening tests, used a single perspective and did not factor in the indirect costs other than those incurred for screening. Duration of diabetes and the HbA 1c level were also not examined, which may influence the efficacy of screening at different intervals. Unlike most models, they do not note increasing surveillance intervals once diabetic retinopathy is detected on screening.
In a US-based model, Rein et al. [42] compared three screening modalities (annual screening using dilated ophthalmoscopy, annual digital photography screening and biennial ophthalmoscopy screening) and concluded that biennial eye evaluation was the most cost-effective treatment option when the ability to detect other eye conditions (age-related macular degeneration and glaucoma) was included in the model. Telemedicine was most cost-effective when other eye conditions were not considered or when telemedicine was assumed to detect refractive error. Annual eye evaluation recommendation was costly compared with either treatment alternative. costing methodologies and are based on different clinical practices. The limitations of economic studies mainly relates to their various assumptions. Some of the models did not include the pathway to blindness through maculopathy [36, 37, 41] , potentially underestimating the incidence of sight-threatening diabetic retinopathy. Other potential sources of bias from the models include not varying the major inputs of disease progression and mortality [41] , not considering the sensitivity and specificity of various diabetic retinopathy screening tests [41] , using a single perspective without any sensitivity analysis including other perspectives [38] [39] [40] [41] 43] , not factoring in the indirect costs other than those incurred for screening (with a potential bias toward the effectiveness of the programme) [43] , not discounting costs and/or consequences associated with differential timing [38, 39] , not specifying how costs were measured [38, 43] , not measuring all the consequences [38] , not accounting for the duration of diabetes and the HbA 1c level (may influence the efficacy of screening at different intervals) [38, 41, 43] and not accounting for the screening compliance rate [40, 43] .
The vast majority of studies examined in this review were conducted in populations of predominantly European descent. Furthermore, some of the modelling studies including a mixed population overlooked potential variations in retinopathy risk in all the subgroups included [7] , raising the issue of the generalizability of the findings. The susceptibility to diabetic retinopathy and rate of progression may be higher in other ethnic groups (people of African, Hispanic or Native American descent), given the frequency of diabetic retinopathy in these groups [1] and their genetic susceptibility [12, 51] . It may therefore be difficult to extrapolate the results presented here to these groups. In addition, the screening programmes were conducted in high-income countries, where the systems are generally better suited to influence progression of diabetes, than in low-and middle-income countries.
Strengths and limitations of the review
The strengths of this review include the appraisal of the totality of the evidence on screening interval for diabetic retinopathy, especially that from real-world screening programmes, and thus its potential utility in helping to choose the most appropriate screening interval in guidelines. However, any policy modification or adoption should be followed by an extensive evaluation, especially in low-and middle-income countries, as the vast majority of existing studies have been conducted in the Western world. The review is limited by the partial reliance on modelling studies with their many assumptions, rather than real-life data. Also, we ranked the quality of economic studies using a scoring system; such a rating is not completely without subjectivity. Finally, our ability to assess publication bias was limited.
Conclusions
This review of evidence suggests that a 2-year screening interval for people with diabetes and no diabetic retinopathy at diagnosis may be safely adopted. However, this is contingent upon the availability of facilities to conduct appropriate eye examinations and deliver appropriate care to people detected. Available data, especially from real-life screening programmes, was mainly retrospective and originated from studies in Caucasians; additional prospective data from non-Caucasian populations, especially in low-and middle-income countries, are therefore needed. Such data may confirm whether the suggested 2-year screening interval is safe and sustainable in any population and/or any health system. The choice of a screening interval should account for the context; consideration should be given to capacity of the health system to perform screening at the indicated frequency and to provide appropriate treatment.
